Whether CPI also recruits CD4+ CTLs is not yet known, but the expansion of NY-ESO-1 specific, EOMES+ CD4+ T cells able to lyse autologous tumor cells in a MHC-class II restricted manner was described in melanoma patients after Ipilimumab infusion [95]. The gene discussed is CD4; the disease is melanoma.